PlatinumRx, an Indian online pharmacy focused on affordable medicine alternatives, is discussing a $32 million funding round led by Belgium’s Sofina Ventures. This round could value the company near $200 million, significantly up from its previous financing milestones.
- PlatinumRx targets $32M round led by Sofina Ventures at $150-200M valuation
- Startup offers affordable medicine substitutes, serving over 1 million customers
- Funding will boost supply chain, fulfillment centers, and tech development
What happened
Online pharmacy startup PlatinumRx is in advanced discussions to raise approximately $32 million in a new funding round led by Belgium-based Sofina Ventures. The talks suggest a valuation range for the Bengaluru-based company between $150 million and $200 million, marking a significant increase from its previous funding rounds.
The company last raised $6 million in a Series A round in September 2025, supported by Stellaris Venture Partners and India Quotient. Prior to that, it secured $800,000 in seed funding in April 2024, also led by India Quotient. The discussions for this new round are ongoing, and final terms, including valuation and investor participation, remain subject to change.
Why it matters
PlatinumRx operates a platform dedicated to providing affordable alternative medicines with the same composition as prescribed brands, particularly targeting recurring and chronic medicine users. This approach addresses a key challenge in healthcare accessibility in India by lowering medicine costs without compromising effectiveness.
The new capital injection is expected to bolster the company’s supply chain infrastructure, expand its fulfillment capabilities with additional centers, and enhance its technology teams. These improvements will strengthen PlatinumRx’s position in a competitive and rapidly growing online pharmacy market, which continues to attract significant investor interest.
What to watch next
Stakeholders and industry observers will be monitoring the finalization of this funding round, including the confirmed investment amount, valuation, and participation from existing backers like Stellaris Venture Partners and India Quotient. The outcome will impact PlatinumRx’s growth trajectory and competitive positioning in India’s digital healthcare segment.
Further developments in this sector include increased competition from quick commerce medicine delivery startups and large-scale funding rounds by sector peers. How PlatinumRx leverages the fresh capital to scale operations and innovate its product offerings will be critical to its ability to capture a larger share of India’s expanding online pharmacy ecosystem.